Preventing platelet adhesion and subsequent aggregation at sites of vascular injury by blocking the VWF/GPIb interaction represent an attractive target for the treatment of important human diseases including thrombotic thrombocytopenic purpura, acute coronary syndrome, and stroke. This evidence concerns the gene VWF and Stroke.